Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections

Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections

Abstract Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants, the immunocompromised, and the elderly. RSV infects the airway epithelium via the apical membrane and almost exclusively sheds progeny virions back into the airway mucus (AM), making RSV difficult to ta...

Full description

Bibliographic Details
Main Authors: Morgan D. McSweeney, Sarhad Alnajjar, Alison M. Schaefer, Zach Richardson, Whitney Wolf, Ian Stewart, Pun Sriboonyapirat, Justin McCallen, Ellen Farmer, Bernadette Nzati, Sam Lord, Brian Farrer, Thomas R. Moench, Priya A. Kumar, Harendra Arora, Raymond J. Pickles, Anthony J. Hickey, Mark Ackermann, Samuel K. Lai
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Advanced Science
Subjects:
mAb nebulization
monoclonal antibody
nebulization
respiratory syncytial virus
RSV
Online Access:https://doi.org/10.1002/advs.202306729

Internet

https://doi.org/10.1002/advs.202306729

Similar Items